Hariprasad Gali, Ph.D.
The main research focus of Dr. Gali’s laboratory is to develop new Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) radiopharmaceuticals for molecular and functional imaging applications. Currently, Dr. Gali’s research is focused on the following two projects:1) Development of radiopharmaceuticals for PET renography; and 2) Development of aminopeptidase N targeted radiopharmaceuticals for imaging tumor angiogenesis.
Education & Experience
Ph.D. in Chemistry
University of Missouri 1999
M.Sc. in Chemistry
University of Hyderabad, India1995
B.Sc. in Math, Physics, Chemistry
Osmania University, India1993
Publications & Presentations
- Babu A, Amreddy N, Muralidharan R, Pathuri G, Gali H, Chen A, Zhao Y D, Munshi A, Ramesh R. Chemodrug delivery using integrin-targeted PLGA-Chitosan nanoparticle for lung cancer therapy. Scientific reports. 2017; 7 : 14674
- Mohammed A, Janakiram N B, Madka V, Pathuri G, Li Q, Ritchie R, Biddick L, Kutche H, Zhang Y, Singh A, Gali H, Lightfoot S, Steele V E, Suen C S, Rao C V. Lack of chemopreventive effects of P2X7R inhibitors against pancreatic cancer. Oncotarget. 2017; 8 : 97822-97834
- Gali H. An open-source automated peptide synthesizer based on arduino and python. SLAS technology. 2017; 22 : 493-499
- Cheki M, Gali H. Preliminary radiation dosimetry of a novel PET radiopharmaceutical 68Ga-NODAGA-glycine in comparison with 99mTc-DTPA in renal studies. Hellenic journal of nuclear medicine. 2017; 20 : 241-246
- Pathuri G, Hedrick A F, Awasthi V, Cowley, Jr B D, Gali H. Synthesis and in vivo evaluation of ortho-[124I]iodohippurate for PET renography in healthy rats. Appl Radiat Isot. 2016; 115 : 251-5